道彤投资
@author-1784793658606
以生命科学为根，向硬科技生长
Articles
How to Invest in Brain-Computer Interfaces? Dalton Venture's Lin Zhengcheng Breaks Down the Underlying Investment Logic at WAIC
**During the 2026 World Artificial Intelligence Conference (WAIC), Lin Zhengcheng, Partner at Dalton Venture, was invited to join Observer Network's *Zhi Guan WAIC 2026* livestream for nearly an hour of in-depth discussion on frontier technologies including brain-computer interfaces and AI for Science.** Rather than chasing industry buzzwords, Dalton Venture hoped to use this opportunity to present a long-developed research framework: as artificial intelligence continues to push toward the frontiers of science, the life sciences
Astribot Releases Self-Developed Home Implicit World Action Model Lumo-2 | DaoTong Family
Recently, **Daotong Family company** — cable-driven AI robotics firm **Astribot** — unveiled its self-developed second-generation embodied foundation model, Lumo-2: the industry's first household latent world-action model, alongside Agent Philia, a physical AI symbiotic agent, advancing its "AI model — embodied OS — cable-driven
Rushi Robotics Closes 100 Million Yuan Pre-A Round to Build Embodied Intelligence Platform for Real-World Elder Care Scenarios | Tongcheng Family
Recently, **Dalton Venture portfolio company Shanghai Rushen Robotics Technology Co., Ltd.** (hereinafter referred to as "Rushen Robotics") **announced the completion of a 100-million-yuan Pre-A funding round**, with investment from Qingsong Capital, leading listed computing power company Range Intelligent Computing Technology, and Pinghu Zexin. This round of financing will strongly support Rushen Robotics' continuous operation in real elderly care scenarios, data generation, and model iteration. This follows Dalton Venture's sole investment in Rushen Robotics in September 2025
Two rounds in six months: Datong Capital continues to double down as Gestalt Technology closes a 420 million yuan angel+ round | Datong Family --- Gestalt Technology (格式塔科技) has completed a 420 million yuan angel+ financing round, with existing investor Datong Capital (道彤资本) leading the round. This marks Datong's second consecutive investment in the company within six months, following its participation in Gestalt's angel round earlier this year.
On July 3, 2026, **Gestala**, a **Daotong Family portfolio company** and China's first company focused on ultrasound-based brain-computer interfaces, announced the completion of a **420 million RMB angel+ funding round**, while simultaneously holding an inauguration ceremony for its Shanghai headquarters — establishing a dual-headquarters strategic layout across "Chengdu + Shanghai".
Dalton Venture's Sun Qi: Dig Deep Into Your Own Track, and Wait for Your Own Market | Dalton Insights
Over the past year, TongDao's main focus areas have been three: brain-computer interfaces, bio-manufacturing, and new materials.
Racing to Compete in the Trillion-Dollar Blue Ocean of Bio-Manufacturing, Heart Capital's Bio-Manufacturing Fund Injects Strong Patient Capital into the Industry
Dalton Venture launched Shanghai's first bio-manufacturing industry fund, injecting strong patient capital into the sector.
Kongshan Ci Completes Series A Funding: Full-Stack Brain-Computer Neural Regulation Platform Leads New Paradigm in Psychiatric Diagnosis and Treatment | TongNews
Existing shareholder Dalton Venture continued to increase its stake.
Exclusive Interview with Professor Nie Zaiqing: Is the Biopharma Version of "AI Lobster" Here? Shuimu Molecular's Dual-Wheel Model of "Proprietary Pipeline + Tool Empowerment" | Tong's Family
An **AIR incubated company and Tongtou Family portfolio company**, **Shuimu Molecular** has emerged as one of the most promising benchmark enterprises in AI-driven drug discovery, pursuing a dual-engine strategy of "tool empowerment + proprietary pipeline development." Its core achievements include the ChatDD intelligent agent framework, the OpenBioMed open-source platform, Shuimu Zhiliao — a new consumer-facing "super brain" tool for life sciences — and multimodal large models.
Dalton Venture Selected as First-Batch Fund Manager for Hong Kong's Optimized Innovation and Technology Venture Fund Scheme
Leveraging a Hong Kong-based fund, DoTown deepens its cross-border innovation strategy bridging mainland China and the Greater Bay Area
Bangyun Medical Closes Nearly 100 Million Yuan Angel Round Led by Dalton Venture, Accelerating Upgrading and Global Innovation in Advanced Wound Closure | Dalton News
Dedicated to becoming a leading benchmark in China's domestic wound closure space.